KEY FEATURES • High temperature resistance • Biocompatible • Brilliant colors • Multi sterilizable • Hydrolytic stability • Chemical resistance • Flame resistance • High mechanical performance • Food contact compliant APPLICATIONS • FDA medical & dental devices • Sterilization trays • Aircraft interiors • Automotive lighting • Chemical handling • Sensors and pumps • Plumbing fittings & manifolds • Food service trays • Gears & bushings • Membranes • Connectors For more information, email info.colorant.chromatics@avient.com or call +1.860.626.3029 1.844.4AVIENT www.avient.com Copyright © 2021, Avient Corporation.

Trendwatch™ Overcoming 5G Component Challenges (English)

Trendwatch™ Overcoming 5G Component Challenges (English)

Safety & Health Indemnity. Buyer acknowledges that Seller has furnished to Buyer Material Safety Data sheets, which include warnings together with safety and health information concerning the Product and/or the containers for such Product.

SAFETY & HEALTH INDEMNITY Buyer acknowledges that Seller has furnished to Buyer Material Safety Data Sheets as required under applicable laws and regulations, which include warnings together with safety and health information concerning the Product and/or the containers for such Product.

Ask for our non-toxic prototype materials for health technology applications, too!

They provide a proven, effective and durable solution for countering microbe growth in finished plastic parts used in health and wellness applications.

There are growing concerns over the health hazard of PFAS, and a strong push from regulatory bodies and companies to progressively ban them.

Versaflex™ TF Adhesive Thermoplastic Elastomers (TPEs) for Textile Fabrics As consumers are becoming more health- conscious, there’s a steady increase in the demand for functional, lightweight, and comfortable fitness clothing that is also visually appealing.

Page 3 Strategy and Execution Drive Results 90% $22 $24 PolyOne Stock Price 50% $18 $20 $22 S&P 500 (relative performance) 30% $12 $14 $16 S&P 500 (relative performance) ‐10% 10% $6 $8 $10 50% ‐30% $0 $2 $4 $ | ‐50%$0 2006 2007 2008 2009 2010 2011 2012 2013 Page 4 Four Pillar Strategy The World’s Premier Provider of SpecializedThe World s Premier Provider of Specialized  Polymer Materials, Services & Solutions Page 5 Spartech – Compelling Strategic Rationale • Spartech expands PolyOne’s specialty portfolio with adjacent  technologies in attractive end markets  Bolt on acquisition with opportunity for global expansion as only Bolt‐on acquisition with opportunity for global expansion, as only  6% of Spartech’s revenues are outside of North America • PolyOne has a proven management team with a track record of  transformational success • Preliminary synergy estimated at $65 million run rate by end of  3year 3  Significant opportunity to expand profitability by leveraging  PolyOne’s four pillar strategy • Substantial potential share price appreciation for all  shareholders f f ll / $ Accretive to EPS in first full year post‐acquisition / $0.50 once  synergies realized Page 6 Mix Shift Highlights Specialty Transformation  Old  PolyOne Transformation 100% 2015 Target 80% In co m e*   65 – 75%40% 60% f O pe ra tin g  34% 43% 45% 65  75% 20%  o f 2%0% 2005 2008 2010 2012 2015 Specialty OI $5M   $46M                        $87M                       $114M                     Target *Operating Income excludes corporate charges and special items JV's PP&S Distribution Specialty Page 7 Proof of Performance 2007 2012 2015 “Where we were” “Where we are” “Where we Where we were Where we are expect to be" 1)  Operating Income % Specialty 3.2% 9.1% 12 – 16% PP&S 6.1% 9.0% 9 – 12% Distribution 3.0% 6.4% 6 – 7.5% 2)  Specialty Platform sss% of Operating Income 20% 45% 65 – 75% 3) ROIC* ( ft t ) 7% 11% 15%3) ROIC* (after‐tax) 7% 11% 15% 4)  Adjusted EPS Growth** N/A 4 yr CAGR = 55% Double Digit  Expansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period **4 yr EPS CAGR calculated using 2012 adjusted EPS vs 2008 adjusted EPS Page 8 Proof of Performance Spartech Opportunity Intermediate  PolyOne Spartech Opportunity 2006 2012 Today Goal “Where we were” “Where we are” “Where  Spartech is”* “Where we can go”were are Spartech is can go Specialty Operating Margin 1.5% 9.1% 2.2% 8.0% – 10.0%  Margin Page 9 *Pro Forma results include Spartech corporate allocations for FY12 ended November 3, 2012 PolyOne 14% Latin America 3% Distribution 2012 Revenues: $4.2 Billion* 2012 Revenues: $4.2 Billion* United States 14% 5% PP&S 20%Specialty 57% Building & HealthCare 1.02 1.20 $1.20 $1.40 ha re End Markets* EPS Growth Construction 14% 17% Industrial 9% 0.27 0 21 0.79 $0.40 $0.60 $0.80 $1.00 Ad ju st ed  E ar ni ng s P er  S Electrical & 0.12 0.21 0.13 $0.00 $0.20 2006 2007 2008 2009 2010 2011 2012 Page 10 * Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms Specialty U it d 2012 Revenues: $2.4 Billion* Solutions United States 59% 9% Latin America Building & C t ti HealthCare   o f S al es 12-16% End Markets* Expanding Profits Construction Electrical & Industrial 15% 1.5% 3.2% 4.3% 5.3% 8.4% 9.1% O pe ra tin g  In co m e  Page 11 2006 2007 2008 2009 2010 2011 2012 2015 O Target* Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms Designed Structures and Solutions United States 2012 Revenues: $0.85 Billion* Solutions 84% Latin America 4% Building & Construction Sign & Advertising 3% Recreation & Leisure Pool & Spa 1% Distribution & Thermoform 2% Operating Income % of Sales 2012 Revenue by Industry Segment* Expanding Profits** Electrical & Electronics 23%Industrial 3% 2.2% 8 ‐ 10% 1% HealthCare 2012 2015 Target  Page 12 *Pro Forma includes FY2012 results for Spartech (11/03/12 YE) **Pro Forma results include Spartech corporate allocations for FY12 Positioned for Earnings Growth 2015 Target Rev: $5B Adj.  EPS: $2.50 Assumptions • High single digit organic  revenue CAGR • Operating margins in mid range  of 2015 targets • No global recession• No global recession • No investment in incremental  PP&S capacity • Completion of 2‐3 midsize  accretive acquisitions • No divestitures  • Housing starts at 85% of 50 year  norm by 2015 R i f t bl b l 3X N t 2012 $ • Remain comfortably below 3X Net  Debt / EBITDA Page 13 Rev: $3.0B Adj.